CBIO (Crescent Biopharma) Construction In Progress: $0.00 Mil (As of Mar. 2026)


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $18.00
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Construction In Progress?

Crescent Biopharma CBIO -3.02% 10 Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Crescent Biopharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Construction In Progress Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Construction In Progress
0.00 0.00

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
CBIO
10GF Score
Crescent Biopharma Inc CBIO
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
Crescent Biopharma (CBIO) has a Construction In Progress of $0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Construction In Progress too high?
Crescent Biopharma's current Construction In Progress is $0.00 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Construction In Progress compare to KYTX and ZURA?
Crescent Biopharma's Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current Construction In Progress of $0.00 Mil. The current Construction In Progress is $0.00 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.00
Price